$8.54
0.00%
Nasdaq, Fri, May 02 2025
ISIN
US16934W1062
Symbol
CMRX
Sector
Industry

Key metrics

Market capitalization $801.08m
Enterprise Value $669.44m
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3,187.83
P/S ratio (TTM) P/S ratio 3,814.69
Revenue growth (TTM) Revenue growth -34.38%
Revenue (TTM) Revenue $210.00k
EBIT (operating result TTM) EBIT $-96.57m
Free Cash Flow (TTM) Free Cash Flow $-75.26m
Cash position $131.64m
EPS (TTM) EPS $-0.99
P/S forward 104.68
EV/Sales forward 87.47
Short interest 3.81%
Show more

Is Chimerix, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Chimerix, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Chimerix, Inc. forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Chimerix, Inc. forecast:

Hold
100%

Financial data from Chimerix, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.21 0.21
34% 34%
100%
- Direct Costs - -
-
-
0.06 0.06
81% 81%
29%
- Selling and Administrative Expenses 22 22
10% 10%
10,576%
- Research and Development Expense 75 75
8% 8%
35,510%
-96 -96
4% 4%
-45,938%
- Depreciation and Amortization 0.09 0.09
0% 0%
43%
EBIT (Operating Income) EBIT -97 -97
4% 4%
-45,984%
Net Profit -88 -88
8% 8%
-42,090%

In millions USD.

Don't miss a Thing! We will send you all news about Chimerix, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Chimerix, Inc. Stock News

Positive
Seeking Alpha
about 2 months ago
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharm...
Neutral
GlobeNewsWire
2 months ago
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025
Neutral
Business Wire
2 months ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix...
More Chimerix, Inc. News

Company Profile

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Head office United States
CEO Michael Andriole
Employees 79
Founded 2000
Website www.chimerix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today